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Reverse transcriptase polymerase chain reaction for the
detection of tyrosinase-mRNA-positive cells in peripheral
blood of melanoma patients, as a possible marker of
hematogenous dissemination, has demonstrated varying
detection rates. This study examined the sensitivity and
reproducibility of the technique using a protocol of
multiple polymerase chain reaction to determine circulat-
ing melanocytic cells. For each of the 123 melanoma
patients included in this study, four nested polymerase
chain reactions were performed from two blood speci-
mens requiring both polymerase chain reactions from at
least one blood sample to be positive to consider a patient
as positive. Thus, a definitive result was obtained in
98% of the cases, whereas only 1.6% lacked conclusive
findings. Thus, we found a correlation between the
tyrosinase detection rate and the clinical stage. Circulating
tyrosinase-mRNA-positive cells were detected in 13% of
patients with primary tumor, 17% with regional skin/
lymph node metastasis, and 44% with distant metastasis.
The prognosis of primary melanoma strongly depends onthe tumor thickness (Breslow, 1970), invasion level(Clark et al, 1969; Morton et al, 1993), and histologictumor type (Garbe and Orfanos, 1992; Barnhill et al,1996). Attempts to detect directly circulating melanoma
cells by morphology, flow cytometry, and conventional cytogenetics
were found to be nonspecific and insufficiently sensitive (Johnson et al,
1995). Detection of tumor cells in the peripheral blood of melanoma
patients by polymerase chain reaction (PCR) amplification has been the
object of recent investigations. The application of reverse transcriptase
polymerase chain reaction (RT-PCR) for tyrosinase mRNA is based
on the fact that the tyrosinase gene encoding for the key enzyme in
melanin biosynthesis is actively expressed only by melanocytic cells.
The technique was first described by Smith et al (1991) in seven
patients with cutaneous melanoma and has subsequently been employed
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Positivity also correlated with known melanoma progres-
sion markers such as gender, tumor thickness, and histol-
ogic type. Positive results were obtained more frequently
in (i) men compared with women, (ii) patients with thick
primary melanomas (.4 mm: 38%) compared with those
with thinner tumors (1.1–4 mm, 22%; ø1 mm, 5%), and
(iii) patients with nonclassifiable (38%), nodular (34%),
and occult primary melanomas (30%) compared with
those with acrolentiginous (17%), superficial spreading
(9%), or lentigo maligna melanoma (0%). These findings
suggest that detection of tyrosinase-mRNA-positive cells
in peripheral blood is not an adequate marker for identify-
ing melanoma patients with distant metastasis. Reverse
transcriptase polymerase chain positivity in early
melanoma stages, however, as corresponding to other
prognostic parameters, may indicate increased risk for
the development of hematogenous metastasis and may
be of value as a progression marker. Key words: metastasis/
polymerase chain reaction/reverse transcription. J Invest Derma-
tol 110:263–267, 1998
by others in larger collectives. Despite its extreme sensitivity in detecting
even a single tumor cell among 107 normal cells (Burchill et al, 1995;
Curry et al, 1996) there are considerable variations in the stage-related
detection rates. These have been reported to range between 0 and
36% for primary tumor, between 0 and 47% for regional skin or lymph
node metastasis, and between 13 and 100% for distant metastasis
(Brossart et al, 1993; Battayani et al, 1995; Hoon et al, 1995; Mellado
et al, 1996; Kunter et al, 1996; Pittman et al, 1996; Reinhold et al,
1997). These variable results necessitate a further, thorough investigation
of the RT-PCR technique in order to assess its clinical validity in the
diagnostic of melanoma.
The primary aim of this study was therefore to examine the
reproducibility of the technique and to establish an evaluation protocol
of the results obtained by multiple RT-PCR analyses from two separate
blood samples from each patient. In a second step, we investigated the
detection rate of tyrosinase-mRNA-positive cells at various clinical
tumor stages. Furthermore, we attempted to define the clinical relevance
of the detection of circulating melanoma cells by correlating the PCR
results with known prognostic melanoma criteria, such as gender,
Breslow thickness, and histologic primary tumor type.
MATERIALS AND METHODS
Patients The study included 123 consecutively selected melanoma patients
(64 females and 59 males, aged 20–87 y). There were 46 patients with primary
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cutaneous tumor (stages I and II), 41 with regional skin or lymph node
metastasis (stage III), and 36 with distant metastatic tumor dissemination (stage
IV). The primary tumor had been classified as nodular melanoma (NM, n 5
44), superficial spreading melanoma (SSM, n 5 33), acrolentiginous melanoma
(ALM, n 5 12), or lentigo maligna melanoma (LMM, n 5 8). In 16 patients,
the primary melanoma could not be classified histologically, and in 10 cases the
primary tumor remained occult. The group examined included five patients
with amelanotic primary melanoma and six with amelanotic metastasis. The
controls were 20 age-matched healthy subjects or nonmelanoma patients who
underwent examinations under identical conditions.
Blood collection and RNA isolation Three 5 ml samples of peripheral
venous blood from each patient were taken into ethylenediamine tetraacetic
acid tubes following one venipuncture, and the first sample was discarded. In
patients undergoing systemic anti-tumor treatment, the blood was taken prior
to a course of therapy and at least 3 wk after the preceding one. Blood samples
were stored at 4°C and processed on ice within 1–2 h. Selective lysis of
erythrocytes was carried out for 10 min in 10 mM KHCO3, 155 mM NH4Cl,
and 0.1 mM ethylenediamine tetraacetic acid. Remaining cells were recovered
by centrifugation, washed, and stored at –70°C. As positive controls, cells of
the human melanoma cell line SKMel-28 (Carey et al, 1976) were added in
decreasing numbers (100, 10, 5, 3, and 1 cells) to 5 ml of control blood.
Total RNA was isolated by guanidium-thiocyanate/phenol-chloroform
extraction as described by Chomczynski and Sacchi (1987) using a kit from
Stratagene (La Jolla, CA). Yield and purity of RNA were determined by
ultraviolet spectroscopy.
Reverse transcription and PCR RT-PCR was performed according to
Smith et al (1991). Each panel of analyzed blood samples included a series of
positive controls (1, 5, 10, 100 cells SKMel-28) as well as blood samples from
nonmelanoma controls and water as negative controls. We used 1 µg of total
cellular RNA for cDNA synthesis. Reverse transcription was carried out in
20 µl of first-strand buffer (50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl2)
containing 10 mM dithiothreitol, 0.09 OD260 units of random oligonucleotides
(Gibco BRL, Berlin, Germany), 500 µM of each dNTP (Pharmacia Biotech,
Uppsala, Sweden), 16.5 units of RNasin ribonuclease inhibitor (Promega,
Madison, WI), and 200 units of RNase H reverse transcriptase (SuperScript II;
Gibco BRL). Samples were incubated at 25°C for 10 min and at 42°C for 50 min.
PCR amplifications were performed in a reaction buffer (10 mM Tris-HCl,
50 mM KCl, 1.5 mM MgCl2) containing 200 µM of each dNTP, and 0.025
units per µl of Taq DNA polymerase (Ampli Taq; Perkin Elmer, New Jersey). A
two-stage nested PCR was applied for amplification of tyrosinase mRNA.
Primers according to Smith et al (1991), matched to different exons of the
tyrosinase gene (Kwon et al, 1987), were purchased from TIB MOLBIOL
(Berlin, Germany). The first round of PCR was carried out in 100 µl of
reaction buffer with 5 µl of the cDNA and 0.4 µM each of the outer primers.
Each sample was overlaid with mineral oil (Sigma, St. Louis, MO). Following
incubation at 94°C for 2 min, 35 cycles (94°C for 30 s, 60°C for 1 min, 72°C
for 2 min) were performed. The second round of PCR was carried out in
50 µl of reaction buffer with 5 µl of a 1:100 dilution of the first PCR product
and 0.4 µM each of the inner primers. Samples were overlaid with mineral oil
and submitted to another 29 cycles (94°C for 30 s, 58°C for 90 s, 72°C for 90 s).
The quality of the cDNA was controlled by PCR for glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH). Primers according to Brossart et al (1993)
were devised from the published sequence (Ercolani et al, 1988) and purchased
from TIB MOLBIOL. A single round of PCR was carried out in 50 µl of the
reaction buffer with 5 µl of the cDNA and 0.4 µM each of the GAPDH
primers. Samples were overlaid with mineral oil and submitted to 30 cycles
(94°C for 45 s, 62°C for 90 s, 72°C for 90 s). PCR products were analyzed on
1.8% agarose gels, and their lengths were compared with the 100 bp DNA
ladder (Gibco BRL).
The following measures against contamination were strictly observed: spatial
separation between pre- and post-amplification, performance of PCR reactions
under a laminar-flow hood, and use of displacement safety tips as well as
powder-free gloves. Only distinct specific bands of expected size were regarded
as positive signals.
Evaluation criteria and statistical analysis For each patient, RNA extrac-
tion and subsequent cDNA synthesis were carried out individually from two
separate blood samples. Two PCR analyses were performed from each cDNA. A
patient was considered positive when both PCR analyses of at least one blood
sample were positive (Table I). The evaluation only included those series in
which at least the control with five SKMel-28 cells yielded a positive result.
For statistical evaluation, the Pearson chi-square test was used to correlate
the PCR results with the gender and histologic tumor type; the Cochrane-
Armitage trend test was used to correlate the PCR results with the clinical
stage and tumor thickness (StatXact 3 for Windows). A multivariate test using
Table I. Four PCR analyses of two separate RNA
preparations were sufficient to obtain a definitive result in
98.4% of 123 melanoma patients examined
1. RNA 2. RNA Final Patients %
analysis analysis evaluation (n)
– – – – negative 82 66.6
1 1 1 1 positive 8 6.5
1 1 – – positive 7 5.7 (84.6%a)
1 1 1 – or – 1 positive 2 1.6
– – 1 – or – 1 negative 5 4.1
– – 1 1 positive 6 4.9
1 – or – 1 1 1 positive 6 4.9 (13.8%b)
1 – or – 1 – – negative 5 4.1
1 – or – 1 1 – or – 1 – 2 1.6 (1.6%c)
Total: 123 100
aFinal evaluation not changed by the result of the second blood sample.
bFinal evaluation changed by the result of the second blood sample.
cNo result was obtained by analyzing two blood samples.
Figure 1. PCR amplification yielded specific bands for tyrosinase
mRNA and GAPDH mRNA. The figure shows agarose gel electrophoresis
of the first and second round of PCR amplification for tyrosinase mRNA with
specific fragments at 287 bp and 207 bp, respectively, as well as the control
PCR for GAPDH mRNA with specific bands at 320 bp. The series included
blood from stage I–IV melanoma patients as well as positive controls (SKMel-
28 cells in declining numbers) and negative controls (blood from nonmelanoma
patients or healthy donors as well as water controls).
logistic regression analysis (SPSS for Windows) was performed to simultaneously
consider the association between the PCR results (dependent variable) and the
clinical stage (stages I–III versus stage IV), the primary melanoma thickness
(ø1 mm versus .1 mm), and the histologic tumor type (SSM/ALM/LMM
versus NM/nonclassifiable) as independent variables.
RESULTS
Reliable results could be achieved in 98% of the cases after performing
four PCR analyses for each patient After the first round of tyrosinase
PCR, specific bands of 284 bp were only obtained from positive
controls (SKMel-28) as well as from six patients with highly advanced
disease. Applying the second round of PCR, specific 207 bp bands
were detected in a total of 29 patients. The series of positive patients
also included three with amelanotic primary tumor, one with amelanotic
melanoma metastasis and three with occult primary melanoma. In
contrast, no tyrosinase mRNA was detected in any of the 20 healthy
controls or nonmelanoma patients. On the other hand, PCR for the
control gene GAPDH resulted in strong specific bands of 320 bp in
all blood samples (Fig 1).
Peripheral blood was examined from a total of 123 melanoma
patients. All four PCR analyses of both RNA preparations yielded
identical results in 90 patients (73%): all analyses were negative in 82
patients and positive in eight patients. The two blood samples yielded
discrepant results in 33 patients (27%). We evaluated these data by a
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Figure 2. RT-PCR detection of circulating melanoma cells correlated
with the clinical stage. The number of positive and negative patients and the
percentage of positive results for RT-PCR detection of tyrosinase mRNA in
the blood of 123 patients are shown in correlation to the clinical stage of
melanoma: stage I/II (primary melanoma), stage III (regional skin/lymph node
metastasis), and stage IV (distant metastasis).
scheme represented in Table I. According to this evaluation, the final
result was not altered by the second blood sample in 14 patients (13%).
Therefore, the final result reflected the findings in the first blood
sample in 104 patients (85%), but was modified after analysis of the
second sample in 17 patients (14%). Only two of 123 patients (1.6%)
had no final result after four PCR analyses due to contradictory findings
in the two blood samples (Table I).
Results of tyrosinase PCR correlated with clinical stage Positive
PCR results were obtained for six of 46 patients (13%) in stages I and
II (primary melanoma) and for seven of 41 (17%) in stage III (regional
skin or lymph node metastasis). The highest positivity rate was detected
in stage IV; 16 of 36 (44%) melanoma patients with distant metastasis
had circulating tumor cells (Fig 2). Thus the detection rate of tyrosinase
mRNA in peripheral blood cells correlated significantly with the
clinical tumor stage (p , 0.0001).
Our evaluation strategy based on four PCR analyses from two
separate RNA preparations was compared with two other assessment
modalities (Fig 3). Regarding a single positive PCR as a positive final
result would increase the proportion of positive patients to 20% in
stages I and II, 33% in stage III, and 47% in stage IV. Evaluating only
the first PCR analysis would reduce the percentage of positive patients
to 4% in stages I and II, 10% in stage III, and 25% in stage IV.
Due to its high amplification rate, nested PCR does not allow direct
quantitative analysis of amplified fragments; however, the actual number
of melanoma cells in a patient’s blood sample could be estimated
by considering the sensitivity of each experiment according to the
concentration series of SKMel-28 cells. Tyrosinase transcripts corres-
ponding to more than five SKMel-28 cells per 5 ml blood were
estimated in 4% of stage I and II, 10% of stage III, and 17% of stage
IV melanoma patients. These data indicate that not only the frequency
of positive PCR results but also the number of circulating melanoma
cells correlated with the clinical tumor stage.
Tyrosinase-mRNA-positive cells were more frequently detected
in male than in female patients In stages I and II, four of 20 male
patients (20%) but only two of 26 female patients (8%) had positive
results. In stage III, five of 22 males (23%) versus two of 19 females
(11%) were positive. In stage IV, eight of 17 men (41%) and eight of
19 women (42%) showed positive PCR results. Thus, considerable
differences between male and female melanoma patients were observed
Figure 3. Variations of RT-PCR positivity applying different evaluation
criteria. The rates of positive results in 123 melanoma patients were determined
according to different evaluation criteria: 1. PCR, evaluation of only the first
PCR performed; 1 pos., consideration of a single positive PCR as a positive
final result; 2 pos., two positive PCR from either of the two blood samples
required for a positive final result. In this study, further evaluation was carried
out using the last schedule based on four PCR from two separate RNA
preparations with two positive PCR as a final positive result.
Table II. Detection rates of circulating melanoma cells
correlated with the primary tumor thickness (n J 108)
Positive PCR resultsb
Tumor thicknessa Stages I and II Stage III Stage IV Frequencyb
ø1.0 mm 1/13 0/3 0/4 1/20 5 5.0%
1.1–4.0 mm 2/21 4/22 7/16 13/59 5 22.0%
.4.0 mm 2/11 3/10 6/8 11/29 5 37.9%
aPrimary tumor thickness according to Breslow (1970).
bNumber of tyrosinase-mRNA-positive patients/total number of patients.
up to stage III, whereas no differences were seen in stage IV, when
dissemination had already occurred. Altogether, circulating tyrosinase-
mRNA-positive cells were detectable in 12 of 64 females (19%) and
17 of 59 males (29%).
Tyrosinase-PCR results correlated with primary tumor
thickness In stages I and II, results were positive for two of 11
patients with primary tumors . 4 mm, two of 21 patients with a 1.1–
4 mm tumor thickness but only one of 13 patients with tumors ø
1 mm (Table II). Altogether, melanomas thicker than 4 mm were
more frequently associated with positive PCR results (38%) than those
with a thickness of 1.1–4 mm (22%) or ø 1 mm (5%). This indicates
a close correlation between the tumor thickness and the occurrence
of circulating melanoma cells (p , 0.005).
Results of tyrosinase PCR correlated with the histologic type
of primary tumor Figure 4 summarizes the results of tyrosinase
PCR in relation to the histologic classification of the primary tumor.
Percentages of positive PCR results varied considerably among the
various types: NM, SSM, ALM, and LMM. In stages I and II, results
were positive for three of 15 patients with NM, none of 19 with SSM,
one of six with ALM, and two of five with nonclassifiable primary
tumor. In stage III, six of 17 patients with NM but only one of nine
with SSM showed positive results. In stage IV, circulating tumor cells
were detected in six of 12 patients with NM, two of five with SSM,
four of seven with nonclassifiable tumors, and three of seven with
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Figure 4. Circulating tyrosinase mRNA correlated with the histologic
type of primary melanoma. RT-PCR detection of tyrosinase mRNA in the
peripheral blood of 111 melanoma patients (stages I–IV) is shown in relation
to the histologic type of the primary tumor: NM, nodular melanoma; SSM,
superficial spreading melanoma; LMM, lentigo maligna melanoma; ALM,
acrolentiginous melanoma; nonclass, histologically nonclassifiable melanoma.
occult primary melanoma. Altogether, NM or histologically nonclassi-
fiable tumor types and occult primary tumors were more frequently
associated with a positive tyrosinase PCR (34%, 38%, and 30%,
respectively) than ALM, SSM, or LMM (17%, 9%, and 0%, respectively)
(p , 0.005).
Multivariate analysis to simultaneously consider the association
between PCR results (dependent variable) and the clinical data (inde-
pendent variables) disclosed significant differences among various disease
stages (stages I–III versus stage IV, p , 0.01) and among histologic
tumor types (SSM/ALM/LMM versus NM/nonclassifiable, p , 0.005).
Altogether, male patients with distant metastasis originating from
nodular or nonclassifiable primary melanoma thicker than 1 mm most
frequently had circulating tyrosinase-mRNA-positive cells.
DISCUSSION
Early recognition of disease progression is essential for improvement
of the management of melanoma patients. The development of RT-
PCR as applied for tyrosinase mRNA has opened up new perspectives,
enabling the detection of a single tumor cell in 2 ml blood (Smith
et al, 1991); however, considerable variations in the positivity rates of
previous studies (Brossart et al, 1993; Battayani et al, 1995; Hoon et al,
1995; Mellado et al, 1996; Kunter et al, 1996; Pittman et al, 1996;
Reinhold et al, 1997) may be due to different evaluation methods.
Furthermore, extremely high amplification rates and the additional
procedural steps of the nested PCR may enhance the risk of carry-
over contamination and artefacts due to traces of skin and hair. Our
investigations were prompted by the need for a reliable RT-PCR to
accurately determine the value of this procedure in the diagnostic of
melanoma. Our primary aim was to establish a defined protocol based
on the evaluation of four PCR analyses following two separate RNA
preparations from two different blood samples. Using this protocol,
we have observed different findings for the two blood samples in 25%
of the patients (31 of 123). In view of the precautions and controls to
prevent false positive and false negative results, discrepant results may
occur, for example, in those patients with very small numbers of
circulating tumor cells, which were indeed present in one blood sample
and absent in the other. Furthermore, sensitivity varies according to
the rate of reverse transcription and PCR amplification. PCR for
GAPDH, however, yielded strong signals for all blood samples, thus
excluding insufficiency of RNA preparation and cDNA synthesis.
The nested PCR with 64 cycles detected 1–5 SKMel-28 cells per
5 ml blood, thus being well within the reported sensitivity ranges.
Under these conditions, analysis of a second blood sample was
considered necessary to obtain reliable results in 14% of the patients.
In a total of only 1.6%, four PCR analyses did not yield final results
according to the proposed evaluation scheme.
Our findings in 123 melanoma patients confirmed a significant
correlation between the clinical stage and the detection of circulating
tyrosinase-mRNA-positive cells (p , 0.0001), as has been reported
previously, whereas nonmelanoma donors remained negative. Highest
detection rates were observed in stage IV melanoma patients (44%).
Therefore, lack of detection of tyrosinase mRNA in the blood does
not necessarily exclude the existence of distant metastasis in melanoma
patients, indicating that the RT-PCR technique cannot be used as a
diagnostic procedure for melanoma staging. We also conclude that the
existence of established distant metastasis does not necessarily imply
the continued presence of tyrosinase-positive cells in the blood. This
may indicate either an intermittent spread of tumor cells or an arrest
of disease progression due to elimination of circulating cells via active
defence mechanisms. It is conceivable, however, that the continued
presence of circulating melanoma cells after the establishment of distant
metastasis may indicate ongoing tumor progression. In a recent report,
it has been concluded that PCR for tyrosinase mRNA is not an
adequate marker of metastatic progression because circulating tumor
cells were not constantly detectable in the blood (Reinhold et al, 1997);
this is in agreement with our preliminary studies (data not shown). A
possible limitation of the method is the lack of detection of tyrosinase-
negative melanoma cells. Tyrosinase and other pigment genes in
melanoma may be generally repressed, as has been shown in vitro (Eberle
et al, 1995). One should note, however, that tyrosinase transcripts were
also detected in peripheral blood from patients with amelanotic primary
tumors or amelanotic metastases, indicating that tyrosinase transcription
is not limited to pigmented tumors. In support of this, amplification
of tyrosinase transcripts by nested PCR yielded positive signals in 10
of 14 human melanoma cell lines, including weakly pigmented or
amelanotic lines (Eberle et al, 1995).
Long-term clinical follow-up studies are required to investigate
whether the presence of tyrosinase-mRNA-positive cells in stages I
and II (13%) and stage III (17%) melanoma patients should be considered
a risk factor for developing hematogenous metastasis. Nevertheless, we
found a significant correlation between tyrosinase PCR and known
prognostic melanoma markers such as gender, thickness, and histologic
type of the primary tumor. This correlation may indicate the value of
the technique as a melanoma progression marker: positive results were
found more frequently in male than in female patients, which is
consistent with epidemiologic data confirming a better prognosis in
women (Tho¨rn et al, 1987; Sirott et al, 1993; Schuchter et al, 1996).
According to the Breslow index, positive results were more frequent
in patients with primary melanomas measuring .4 mm than in those
with tumors measuring ,4 mm. These data coincide with a higher
progression risk in patients with thick primary melanomas (Breslow,
1970); anyhow, the data indicate that even thin melanomas measuring
,1 mm may disseminate tyrosinase-mRNA-positive cells in the blood.
The correlation of positive PCR findings in patients with prognostically
unfavorable nodular melanoma or histologically nonclassifiable or occult
primary melanoma, compared with the lower PCR rates in patients
with acrolentiginous melanoma, superficial spreading melanoma, and
lentigo maligna melanoma, may reflect a lower metastatic risk in these
last subtypes.
In conclusion, quadruplicate performance of PCR analyses for
detection of tyrosinase positive cells in peripheral blood may enhance
the validity of the technique. The RT-PCR may be of value as a
progression marker for identifying hematogenous dissemination risk
rather than for identifying distant melanoma metastasis. The detection
of circulating tumor cells may serve to identify patients at high risk for
developing hematogenous melanoma metastasis, especially those with
thin primary tumors. Long-term studies of PCR-positive patients are
required to better recognize its overall clinical relevance and predictive
value. Detection of circulating melanoma cells during anti-cancer
treatment may also be useful for better evaluating therapeutic inter-
ventions.
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